Sorafenib in Advanced Hepatocellular Carcinoma

M. Llovet, Josep; Ricci, Sergio; Mazzaferro, Vincenzo; Hilgard, Philip; Gane, Edward; Frédéric Blanc, Jean; Cosme de Oliveira, André; Santoro, Armando; Raoul, Jean‐Luc; Forner, Alejandro; Schwartz, Myron; Porta, Camillo; Zeuzem, Stefan; Bolondi, Luigi; F. Greten, Tim; R. Galle, Peter; François Seitz, Jean; Borbath, Ivan; Häussinger, Dieter; Giannaris, Tom; Shan, Minghua; Moscovici, M.; Voliotis, D.; Bruix, Jordi

doi:10.1056/nejmoa0708857

Public

Sorafenib in Advanced Hepatocellular Carcinoma

Published in New England Journal of Medicine • Jul 23, 2008

Authors:

Josep M. Llovet

Sergio Ricci

Vincenzo Mazzaferro

Abstract

BACKGROUND: No effective systemic therapy exists for patients with advanced hepatocellular carcinoma. A preliminary study suggested that sorafenib, an oral multikinase inhibitor of the vascular endothelial growth factor receptor, the platelet-derived growth factor receptor, and Raf may be effective ...

Subject

Sorafenib

Hepatocellular carcinoma

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!